
PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Products of "PD-1/PD-L1"
Sort by
(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstratingFormula:C72H99F3N20O23Purity:98%Color and Shape:SolidMolecular weight:1669.67ASC-69
CAS:ASC-69 (APY69) is a promising potent inhibitor of the PD-1/PD-L1 signaling pathway, classified as a small-molecule compound [1].Formula:C19H19N7Purity:98%Color and Shape:SolidMolecular weight:345.4PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.Color and Shape:Odour LiquidLon-TK
Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.Formula:C24H28Cl2N2O3S2Color and Shape:SolidMolecular weight:527.53Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.Color and Shape:Odour LiquidBMS-1166
CAS:BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.Formula:C36H33ClN2O7Purity:99.22%Color and Shape:SolidMolecular weight:641.11Ref: TM-T5697
1mg74.00€5mg155.00€10mg225.00€25mg429.00€50mg635.00€100mg944.00€200mg1,264.00€1mL*10mM (DMSO)208.00€ARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:SolidMolecular weight:568.67PD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.37%Color and Shape:SolidMolecular weight:348.44Ref: TM-T9651
1mg60.00€2mg89.00€5mg134.00€10mg188.00€25mg314.00€50mg429.00€100mg565.00€500mg1,121.00€1mL*10mM (DMSO)148.00€PD-L1-IN-7
CAS:PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.Formula:C46H50N6O7Color and Shape:SolidMolecular weight:798.93TQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).Color and Shape:Odour LiquidPD-1/PD-L1-IN-26
CAS:PD-1/PD-L1-IN-26 is a strong inhibitor with IC50 of 0.0380 μM that may boost immune response in cancer by aiding CD4+ T cell entry to tumors.Formula:C43H52N4O8Purity:98%Color and Shape:SolidMolecular weight:752.89PD-1-IN-17
CAS:PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.Formula:C13H22N6O7Purity:99.6%Color and Shape:SolidMolecular weight:374.35PD-L1-IN-2
CAS:PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity.Formula:C33H38N4O6Purity:98%Color and Shape:SolidMolecular weight:586.68LTB
LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).Formula:C53H59Cl2N3O7S2Color and Shape:SolidMolecular weight:985.09PDL-1 cpd 10
CAS:PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.Formula:C21H23N5O2Purity:97.08%Color and Shape:SolidMolecular weight:377.44Ref: TM-T9359
1mg55.00€5mg117.00€10mg187.00€25mg393.00€50mg562.00€100mg787.00€200mg1,035.00€1mL*10mM (DMSO)134.00€LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormula:C27H27N3O5SPurity:98%Color and Shape:SolidMolecular weight:505.59ARB-272572 hydrochloride
CAS:ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.Formula:C32H36N6O4·xClHPurity:99%Color and Shape:SoildMolecular weight:568.68(Free base)2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.Formula:C35H45N5O6Color and Shape:SolidMolecular weight:631.76PD-1/PD-L1-IN-33
CAS:PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM.Formula:C26H27N5OPurity:98%Color and Shape:SolidMolecular weight:425.53Enpp-1-IN-25
CAS:Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.Formula:C15H21N5O4SColor and Shape:SolidMolecular weight:367.423